

Author Relationships With Industry and Other Entities (Comprehensive)—2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure (December 2015)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
Clyde W. Yancy <i>(Chair)</i>	Northwestern University Feinberg School of Medicine, Division of Cardiology— Professor of Medicine and Chief; Diversity and Inclusion—Vice Dean	None	None	None	• PCORI†	• JAMA Cardiology (Deputy Editor)*	None
Mariell Jessup <i>(Vice Chair)</i>	University of Pennsylvania— Professor of Medicine	None	None	None	None	• ABIM† • AHA† • Up to Date	None
Biykem Bozkurt	Michael E. DeBakey VA Medical Center—The Mary and Gordon Cain Chair and Professor of Medicine	None	None	None	• Novartis†	• ABIM	None
Javed Butler	Stony Brook University— Division Chief of Cardiology	<ul style="list-style-type: none"> • Bayer* • Boehringer Ingelheim* • CardioCell* • Janssen Pharmaceuticals • Medscape • Medtronic • Merck* • Novartis* • PharmaIn • Relypsa* • Stealth Peptide • Takeda† • Trevena* • Z Pharma • Zensun 	• Novartis*	None	<ul style="list-style-type: none"> • Amgen (DSMB)* • Corvia Medical (DSMB) • European Union* • NIH* 	<ul style="list-style-type: none"> • AHA (Deputy Chief Science Officer)* • American Heart Journal (Editorial Board)† • European Journal of Heart Failure (Associate Editor)† • HFSA (Executive Council Member)† • JACC† • JACC: Heart Failure† • NIH • St. Jude Medical 	None
Donald E. Casey, Jr	Thomas Jefferson College of Population Health—Adjunct Faculty; Alvarez & Marsal IPO4Health—Principal and	None	None	None	None	None	None

	Founder						
Monica M. Colvin	University of Michigan—Associate Professor of Medicine, Cardiology	None	None	None	• Scientific Registry of Transplant Recipients/HRSA*	• CareDX • Thoratec	None
Mark H. Drazner	University of Texas Southwestern Medical Center—Professor, Internal Medicine	None	None	• Trevena*	• AHA*	• Alnylam • DCRI/Otsuka • AHA Circulation (Senior Associate Editor)† • NHLBI–GUIDE-IT (Co–PI) • St. Jude Medical (HF Fellowship)* • Up to Date	None
Gerasimos S. Filippatos	National and Kapodistrian University of Athens; Attikon University Hospital, Department of Cardiology, Heart Failure Unit—Professor of Cardiology	None	None	None	• Bayer (Steering Committee)* • Bayer (DSMB) • Cardiorentis (Steering Committee)† • European Union* • Medtronic (Steering Committee)† • Novartis (Steering Committee)* • Servier Pharmaceuticals (Steering Committee)* • Vifor (Endpoint Adjudication Committee)	• European Heart Journal (Associate Editor)	None
Gregg C. Fonarow	Ahmanson-UCLA Cardiomyopathy Center—Director; UCLA Division of Cardiology—Co-Chief	• Amgen • Janssen Pharmaceuticals • Medtronic • Novartis*	None	None	• Medtronic–IMPROVE-HF (Steering Committee)† • NHLBI* • NIH/NIAID* • Novartis*	• ACC/AHA Task Force on Data Standards† • ACC/AHA Task Force on Performance Measures (Chair-Elect)† • ACTION Registry GWTG Steering Committee (Chair)† • AHA Consumer Health	None

						Quality Coordinating Committee† • AHA Manuscript Oversight Committee† • GWTG Steering Committee (PRT)† • JAMA Cardiology (Associate Editor)†	
Michael M. Givertz	Brigham and Women's Hospital—Professor of Medicine	<ul style="list-style-type: none"> • Cardioxyl • Merck • Novartis 	None	None	• BioControl (Clinical Events Committee)	None	None
Steven M. Hollenberg	Cooper University Hospital—Director, Coronary Care Unit, Professor of Medicine	None	None	None	None	None	None
JoAnn Lindenfeld	Vanderbilt Heart and Vascular Institute—Director, Advanced Heart Failure and Transplant Section—Professor of Medicine	<ul style="list-style-type: none"> • Abbott • Boston Scientific • Cardiomems* • CVRx • Janssen Pharmaceuticals • Novartis • Relypsa* • RESMED* 	None	None	<ul style="list-style-type: none"> • AstraZeneca† • Novartis* • St. Jude Medical* 	• JACC HF (Deputy Editor)	None
Frederick A. Masoudi	University of Colorado, Denver—Associate Professor of Medicine, Division of Cardiology	• ABIM	None	None	<ul style="list-style-type: none"> • ACC* • ACC-NCDR* • AHRQ* 	<ul style="list-style-type: none"> • Circulation (Associate Editor) • JournalWatch Cardiology (Associate Editor) 	None
Patrick E. McBride	University of Wisconsin School of Medicine and Public Health—Professor of Medicine and Family Medicine; Associate Director, Preventive Cardiology	None	None	None	• NIH-NIDDK (DSMB)	None	None
Pamela N. Peterson	University of Colorado, Denver Health Medical Center—Associate Professor	• ACC*	None	None	None	• JAHA (Associate Editor)*	None

	of Medicine, Division of Cardiology						
Lynne W. Stevenson	Brigham and Women's Hospital Cardiovascular Division—Director, Cardiomyopathy and Heart Failure Program	• St. Jude Medical	None	None	<ul style="list-style-type: none"> • Novartis—PARENT (PI) • NHLBI • NHLBI—INTERMACS (Co-PI)† • St. Jude Medical 	• Circulation Heart Failure (Senior Associate Editor)†	None
Cheryl Westlake	Azusa Pacific University—Professor and Associate Dean, International and Community Programs	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; ABIM, American Board of Internal Medicine; AHRQ, Agency for Healthcare Research and Quality; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; GWTG, Get With The Guidelines; HF, heart failure; HFSA, Heart Failure Society of America; HRSA, Health Resources and Services Administration; HSAG, Health Services Advisory Group; IMPROVE-HF, Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; JAHA, Journal of the American Heart Association; PCORI, Patient-Centered Outcomes Research Institute; PI, principal investigator; PRT, pharmaceutical round table; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.